Antimicrobial treatment of intra-abdominal infections

Area of Science:

• Infectious Diseases
• Pharmacology
• Surgical Infections

Background:

• Increasing antibiotic resistance in key pathogens (e.g., pneumococci, enterococci, anaerobes, gram-negative rods) complicates treatment.
• Emergence of novel antibiotics (e.g., piperacillin/tazobactam) and updated dosing strategies (e.g., single daily aminoglycoside dosing) necessitate revised management protocols.

Purpose of the Study:

• To review current therapeutic approaches for intra-abdominal infections.
• To emphasize management strategies for peritonitis, cholecystitis, cholangitis, and diverticulitis.
• To incorporate new concepts in treating enterococcal infections, bacterial/fungal peritonitis, and preventing spontaneous bacterial peritonitis.

Main Methods:

• Literature review focusing on recent developments in antibiotic resistance and novel therapeutic agents.
• Analysis of current guidelines and emerging treatment concepts for specific intra-abdominal infections.
• Inclusion of practical recommendations on antibiotic dosing, cost-effectiveness, and the role of invasive procedures.

Main Results:

• Significant shifts in antibiotic susceptibility patterns require careful pathogen-directed therapy.
• Newer antibiotics and optimized dosing regimens offer improved efficacy and potentially reduced toxicity.
• Evidence-based recommendations for managing diverse intra-abdominal infections, including specific antibiotic choices and invasive interventions, are presented.

Conclusions:

• Management of intra-abdominal infections must adapt to evolving antibiotic resistance and new treatment options.
• A comprehensive approach integrating updated pharmacological data and procedural considerations is crucial for optimal patient outcomes.
• This review provides clinicians with actionable insights for effectively treating complex intra-abdominal infections.